Search

Your search keyword '"Zheng, Qiufan"' showing total 131 results
Start Over Author "Zheng, Qiufan"
131 results on '"Zheng, Qiufan"'

4. Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).

Author

Xia, Wen, primary, Yuan, Zhongyu, additional, Wang, Shusen, additional, Zheng, Qiufan, additional, Wu, Zhiyong, additional, Zhong, Muyi, additional, Xu, Fei, additional, Wang, Ying, additional, Ma, Xiaopeng, additional, Ma, Shihui, additional, Zhang, Yuan-Qi, additional, Zhang, Lehong, additional, Shi, Yanxia, additional, Huang, Heng, additional, Xu, Xiangdong, additional, and Li, Haiyan, additional

Published
2024
Full Text
View/download PDF

8. Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-arm, Prospective Study

Author

Jiang, Kuikui, primary, Hong, Ruoxi, additional, Xia, Wen, additional, Lu, Qianyi, additional, Li, Liang, additional, Huang, Jianhao, additional, Shi, Yanxia, additional, Yuan, Zhongyu, additional, Zheng, Qiufan, additional, An, Xin, additional, Xue, Cong, additional, Huang, Jiajia, additional, Bi, Xiwen, additional, Chen, Meiting, additional, Zhang, Jingmin, additional, Xu, Fei, additional, and Wang, Shusen, additional

Published
2023
Full Text
View/download PDF

9. The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence.

Author

Zhou, Danyang, Li, Mei, Xu, Fei, Zheng, Qiufan, Lu, Qianyi, Hong, Ruoxi, and Wang, Shusen

Subjects
EPIDERMAL growth factor receptors, BREAST cancer, CANCER patients
Abstract

To assess the prognostic significance of skin involvement in breast cancer patients with chest wall recurrence (CWR). We retrospectively analyzed the clinicopathological data of breast cancer patients with CWR who were diagnosed pathologically between January 2000 and April 2020. Disease-free survival (DFS) was the time from radical resection for CWR to disease recurrence. Progression-free survival (PFS) was defined as the time from the diagnosis of locally unresectable CWR to the first sign of disease progression. Persistent chest wall progression was defined as three consecutive chest wall progressions with no distant organ involvement. A total of 476 patients with CWR were included in this study. Skin involvement was confirmed in 345 patients. Skin involvement was significantly correlated with a high T stage (p = 0.003), more positive nodes at initial examination (p < 0.001) and lymphovascular invasion (p < 0.001). Kaplan–Meier analysis showed that skin involvement was a predictor of shorter DFS (p < 0.001), including both local disease progression (p < 0.001) and distant disease progression (p = 0.022). Multivariate analysis showed that skin involvement was an independent biomarker for DFS (p = 0.043). Patients with skin involvement were more likely to experience persistent chest wall progression (p = 0.040). After eliminating the potential deviation caused by an insufficient follow-up time, persistent chest wall progression was more likely to be associated with a high N stage (p = 0.002), negative progesterone receptor (PR; p = 0.001) and positive human epidermal growth factor receptor 2 (HER2; p = 0.046) of the primary site, and negative oestrogen receptor (ER; p = 0.027) and PR (p = 0.013) of the chest wall lesion and skin involvement (p = 0.020). Skin involvement was a predictor of poor disease control in patients with CWR and was closely related to persistent chest wall progression. We stratified the prognosis of individualized treatment for breast cancer patients with CWR to provide new insights into the biological behaviours of the disease. Skin involvement is a predictor of poor local disease control in breast cancer patients with CWR and a factor contributing to persistent chest wall progression after CWR. We stratified the prognosis of individualized treatment for breast cancer patients with CWR. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

10. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?—Analysis of genetic and clinical features from a single cancer center database

Author

Ni, Mengqian, primary, Wang, Fang, additional, Yang, Anli, additional, Shao, Qiong, additional, Xue, Cong, additional, Xia, Wen, additional, Xu, Fei, additional, Lin, Xi, additional, Huang, Jiajia, additional, Bi, Xiwen, additional, Hong, Ruoxi, additional, Chen, Meiting, additional, Zheng, Qiufan, additional, Jiang, Kuikui, additional, Xie, Xinhua, additional, Tang, Jun, additional, Wang, Xi, additional, Yuan, Zhongyu, additional, Wang, Shusen, additional, Shi, Yanxia, additional, and An, Xin, additional

Published
2023
Full Text
View/download PDF

12. Construction and validation of a macrophage-related prognostic index to predict the overall survival in patients with early-stage triple-negative breast cancer

Author

Luo, Hanjia, primary, Hong, Ruoxi, additional, Xu, Yadong, additional, Zheng, Qiufan, additional, Xia, Wen, additional, Lu, Qianyi, additional, Jiang, Kuikui, additional, Xu, Fei, additional, Chen, Miao, additional, Shi, Dingbo, additional, Deng, Wuguo, additional, and Wang, Shusen, additional

Published
2023
Full Text
View/download PDF

14. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing

Author

Zhang, Yaxiong, Chang, Lianpeng, Yang, Yunpeng, Fang, Wenfeng, Guan, Yanfang, Wu, Aiwei, Hong, Shaodong, Zhou, Huaqiang, Chen, Gang, Chen, Xi, Zhao, Shen, Zheng, Qiufan, Pan, Hui, Zhang, Lanjun, Long, Hao, Yang, Haoxian, Wang, Xin, Wen, Zhesheng, Wang, Junye, Yang, Hong, Xia, Xuefeng, Zhao, Yuanyuan, Hou, Xue, Ma, Yuxiang, Zhou, Ting, Zhang, Zhonghan, Zhan, Jianhua, Huang, Yan, Zhao, Hongyun, Zhou, Ningning, Yi, Xin, and Zhang, Li

Published
2019
Full Text
View/download PDF

15. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma

Author

Hong, Shaodong, Liu, Dongbing, Luo, Shuzhen, Fang, Wenfeng, Zhan, Jianhua, Fu, Sha, Zhang, Yaxiong, Wu, Xuan, Zhou, Huaqiang, Chen, Xi, Chen, Gang, Zhang, Zhonghan, Zheng, Qiufan, Li, Xiaobo, Chen, Jinghao, Liu, Xingmin, Lei, Mengyue, Ye, Chen, Wang, Jian, Yang, Huanming, Xu, Xun, Zhu, Shida, Yang, Yunpeng, Zhao, Yuanyuan, Zhou, Ningning, Zhao, Hongyun, Huang, Yan, Zhang, Lanjun, Wu, Kui, and Zhang, Li

Published
2019
Full Text
View/download PDF

16. Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study

Author

Ma, Yuyu, primary, Duan, Fangfang, additional, Zhuang, Yue, additional, Song, Chenge, additional, Huang, Jiajia, additional, Xia, Wen, additional, Hong, Ruoxi, additional, Zheng, Qiufan, additional, Wang, Shusen, additional, Shi, Yanxia, additional, Xu, Fei, additional, Yuan, Zhongyu, additional, and Bi, Xiwen, additional

Published
2022
Full Text
View/download PDF

19. Germline Mutational Profiles and Clinicopathological Features Of Hereditary Breast Cancer In Chinese Population

Author

Ni, Mengqian, primary, Wang, Fang, additional, Yang, Anli, additional, Shao, Qiong, additional, Xue, Cong, additional, Xia, Wen, additional, Xu, Fei, additional, Lin, Xi, additional, Huang, Jiajia, additional, Bi, Xiwen, additional, Hong, Ruoxi, additional, Chen, Meiting, additional, Zheng, Qiufan, additional, Jiang, Kuikui, additional, Xie, Xinhua, additional, Tang, Jun, additional, Wang, Xi, additional, Yuan, Zhongyu, additional, Wang, Shusen, additional, Shi, Yanxia, additional, and An, Xin, additional

Published
2022
Full Text
View/download PDF

23. Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis

Author

Zhang, Kai, Hong, Ruoxi, Xu, Fei, Xia, Wen, Kaping, Lee, Qin, Ge, Zheng, Qiufan, Lu, Qianyi, Shi, Yan Xia, Yuan, Zhong Yu, and Wang, Shusen

Subjects
ESR1 mutations, Review, breast carcinoma, ctDNA, cfDNA, meta analysis
Abstract

Background The clinical implication of plasma ESR1 mutations in the estrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who had progressed after prior aromatase inhibitor (AI)-based therapy remains controversial. We conducted the first meta-analysis to investigate the prognostic significance and predictive role of plasma ESR1 mutations in MBC patients with prior exposure to AI therapy. Materials and methods We searched PubMed, Embase, and Cochrane Library databases for eligible studies. Meta-analysis was conducted to calculate combined hazard ratios (HRs) with 95% CIs for progression-free survival (PFS) and overall survival (OS). Subgroup and sensitivity analyses were also performed. Results This study enrolled a total of 1,530 patients with ER-positive MBC cases from six articles, including 429 ESR1 mutation carriers (28.04%). Meta-analysis demonstrated that plasma ESR1 mutation carriers had significantly worse PFS (HR: 1.40, 95% CI: 1.17–1.66; P

Published
2018

25. A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy

Author

Xu, Fei, primary, Zheng, Qiufan, additional, Xia, Wen, additional, Ouyang, Quchang, additional, Pang, Danmei, additional, Yuan, Zhongyu, additional, Shi, Yanxia, additional, Peng, Roujun, additional, Lu, Qianyi, additional, and Wang, Shusen, additional

Published
2020
Full Text
View/download PDF

27. Cover Image: Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center

Author

Lu, Qianyi, Lee, Kaping, Xu, Fei, Xia, Wen, Zheng, Qiufan, Hong, Ruoxi, Jiang, Kuikui, Zhai, Qinglian, Li, Yuan, Shi, Yanxia, Yuan, Zhongyu, and Wang, Shusen

Subjects
Cancer Research, Oncology, Cover Image
Abstract

The cover image is based on the Original Article Metronomic chemotherapy of cyclophosphamide plus methotrexate in advanced breast cancer: Real‐world data and experience of one center (CHJC‐D‐19‐00380) by Shusen Wang et al., https://doi.org/10.1002/cac2.12029. [Image: see text]

Published
2020

28. A Single-Cell Immune Atlas of Triple Negative Breast Cancer Reveals Novel Immune Cell Subsets

Author

Qiu, Si, primary, Hong, Ruoxi, additional, Zhuang, Zhenkun, additional, Zhu, Linnan, additional, Li, Yuan, additional, Zhang, Weimin, additional, Lin, Xinxin, additional, Zheng, Qiufan, additional, Liu, Shang, additional, Zhang, Kai, additional, Huang, Mengxian, additional, Lee, Kaping, additional, Lu, Qianyi, additional, Xia, Wen, additional, Xu, Fei, additional, Hou, Yong, additional, Zhang, Xiuqing, additional, Wang, Jian, additional, Yang, Huanming, additional, Zhan, Qimin, additional, Li, Bo, additional, and Wang, Shusen, additional

Published
2020
Full Text
View/download PDF

30. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.

Author

Wang, Liye, Zhai, Qinglian, Lu, Qianyi, Lee, Kaping, Zheng, Qiufan, Hong, Ruoxi, and Wang, Shusen

Subjects
TRIPLE-negative breast cancer, CHINESE people, CANCER patients, CANCER relapse, NUCLEOTIDE sequencing, GENE rearrangement
Abstract

Triple-negative breast cancer (TNBC) represents about 19% of all breast cancer cases in the Chinese population. Lack of targeted therapy contributes to the poorer outcomes compared with other breast cancer subtypes. Comprehensive genomic profiling helps to explore the clinically relevant genomic alterations (CRGAs) and potential therapeutic targets in very-early-relapsed TNBC patients. Formalin-fixed paraffin-embedded (FFPE) tumour tissue specimens from 23 patients with very-early-relapsed TNBC and 13 patients with disease-free survival (DFS) more than 36 months were tested by FoundationOne CDx (F1CDx) in 324 genes and select gene rearrangements, along with genomic signatures including microsatellite instability (MSI) and tumour mutational burden (TMB). In total, 137 CRGAs were detected in the 23 very-early-relapsed TNBC patients, averaging six alterations per sample. The mean TMB was 4 Muts/Mb, which was higher than that in non-recurrence patients, and is statistically significant. The top-ranked altered genes were TP53 (83%), PTEN (35%), RB1 (30%), PIK3CA (26%) and BRCA1 (22%). RB1 mutation carriers had shorter DFS. Notably, 100% of these patients had at least one CRGA, and 87% of patients had at least one actionable alteration. In pathway analysis, patients who carried a mutation in the cell cycle pathway were more likely to experience very early recurrence. Strikingly, we detected one patient with ERBB2 amplification and one patient with ERBB2 exon20 insertion, both of which were missed by immunohistochemistry (IHC). We also detected novel alterations of ROS1–EPHA7 fusion for the first time, which has not been reported in breast cancer before. The comprehensive genomic profiling can identify novel treatment targets and address the limited options in TNBC patients. Therefore, incorporating F1CDx into TNBC may shed light on novel therapeutic opportunities for these very-early-relapsed TNBC patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

32. Efficacy and safety of pegfilgrastim in prophylaxis of chemotherapy-induced neutropenia in breast cancer patients.

Author

Xia, Wen, primary, Xu, Fei, additional, Yuan, Zhongyu, additional, Xu, Ruilian, additional, Jiang, Yi, additional, Wu, Zhiyong, additional, Lu, Qianyi, additional, Zheng, Qiufan, additional, Hong, Ruoxi, additional, Jiang, Kuikui, additional, Huang, Jiajia, additional, An, Xin, additional, Bi, XiWen, additional, Hong, Yun, additional, Pang, Danmei, additional, Zhang, Anqin, additional, Wang, Xianming, additional, Zhang, Qing, additional, Zhang, Haibo, additional, and Wang, Shusen, additional

Published
2020
Full Text
View/download PDF

35. Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study

Author

Xu, Fei, primary, Lee, Kaping, additional, Xia, Wen, additional, Liao, Hai, additional, Lu, Qianyi, additional, Zhang, Jingmin, additional, Yuan, Huimin, additional, Zhang, Kai, additional, Zheng, Qiufan, additional, Qin, Ge, additional, Zhai, Qinglian, additional, Hong, Ruoxi, additional, Jiang, Kuikui, additional, Li, Yuan, additional, and Wang, Shusen, additional

Published
2020
Full Text
View/download PDF

36. Local treatment for liver oligometastases in breast cancer patients: identification of prognostic factors and exploration of appropriate treatment strategy

Author

Jiang, Kuikui, primary, Xia, Wen, additional, Hong, Ruoxi, additional, Xu, Fei, additional, Zheng, Qiufan, additional, Lu, Qianyi, additional, Lee, Kaping, additional, Li, Yuan, additional, Zhai, Qinglian, additional, Shi, Yanxia, additional, Yuan, Zhongyu, additional, and Wang, Shusen, additional

Published
2020
Full Text
View/download PDF

37. A Single-Cell Immune Atlas of Triple Negative Breast Cancer Reveals Novel Immune Cell Subsets

Author

Qiu, Si, Hong, Ruoxi, Zhuang, Zhenkun, Li, Yuan, Zhu, Linnan, Lin, Xinxin, Zheng, Qiufan, Liu, Shang, Zhang, Kai, Huang, Mengxian, Lee, Kaping, Lu, Qianyi, Xia, Wen, Xu, Fei, Wang, Xi, Tang, Jun, Xiao, Xiangsheng, Wei, Weidong, Yuan, Zhongyu, Shi, Yanxia, Hou, Yong, Zhang, Xiuqing, Wang, Jian, Yang, Huanming, Zhan, Qimin, Li, Bo, and Wang, Shusen

Subjects
animal diseases, bacteria, chemical and pharmacologic phenomena, biochemical phenomena, metabolism, and nutrition
Abstract

Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype, which recently attracts great interest for immune therapeutic development. In this context, in-depth understanding of TNBC immune landscape is highly demanded. Here we report single-cell RNA sequencing results of 9683 tumor-infiltrated immune cells isolated from 14 treatment naïve TNBC tumors, where 22 immune cell subsets, including T cells, macrophages, B cells, and DCs have been characterized. We identify a new T cell subset, CD8+CXCL8+ naïve T cell, which associates with poor survival. A novel immune cell subset comprised of TCR+ macrophages, is found to be widely distributed in TNBC tumors. Further analyses reveal an up-regulation of molecules associated with TCR signaling and cytotoxicity in these immune cells, indicating TCR signaling activation. Altogether, our study provides a valuable resource to understand the immune ecosystem of TNBC. The novel immune cell subsets reported herein might be functionally important in cancer immunity.SIGNIFICANCEThis work demonstrates a single-cell transcriptome atlas of immune cells in treatment naïve TNBC tumors, revealing novel immune cell subsets. This study provides a valuable resource to understand the immune ecosystem of TNBC, which will be helpful for the immunotherapeutic strategy design of TNBC.

Published
2019

38. A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy.

Author

Xu, Fei, Zheng, Qiufan, Xia, Wen, Ouyang, Quchang, Pang, Danmei, Yuan, Zhongyu, Shi, Yanxia, Peng, Roujun, Lu, Qianyi, and Wang, Shusen

Subjects
DRUG efficacy, DISEASE progression, INJECTIONS, CLINICAL trials, CONFIDENCE intervals, ANTINEOPLASTIC agents, TREATMENT effectiveness, DESCRIPTIVE statistics, POSTMENOPAUSE, SURVIVAL analysis (Biometry), ODDS ratio, HORMONE receptor positive breast cancer, PATIENT safety, EVALUATION
Abstract

Lessons Learned: Fulvestrant 500 mg maintenance therapy showed a clinical benefit rate of 76% and median progression‐free survival of 16.1 months in patients who achieved objective responses or disease control after first‐line chemotherapy.Adverse events with fulvestrant maintenance therapy were consistent with the known safety profile of the drug. Background: Evidence for maintenance hormonal therapy after chemotherapy for estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer is scarce. This study aimed to evaluate the efficacy of fulvestrant 500 mg maintenance therapy in patients after first‐line chemotherapy. Methods: We enrolled postmenopausal women with ER‐positive/HER2‐negative advanced breast cancer who attained tumor responses or disease control with four to eight cycles of chemotherapy as first‐line treatment. Fulvestrant 500 mg was injected on days 1, 15, and 29 and every 28 (±3) days thereafter. The primary endpoint was the clinical benefit rate (CBR); the secondary endpoints included the objective response rate (ORR), progression‐free survival (PFS), and safety. Results: We included 58 patients; the median follow‐up duration was 32.6 months. The CBR since commencing fulvestrant maintenance therapy was 76% (95% confidence interval [CI], 63%–86%), and ORR was 14% (95% CI, 6%–25%); eight patients achieved partial response. The median PFS for fulvestrant maintenance therapy was 16.1 months (95% CI, 10.3–21.0 months). Thirty‐nine patients (67%) reported at least one adverse event, of which most were grade 1/2, whereas three patients (5%) reported grade 3 adverse events. Conclusion: Fulvestrant 500 mg is a feasible and promising hormonal maintenance strategy in patients with ER‐positive/HER2‐negative advanced breast cancer who have no disease progression after first‐line chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

39. A Single-Cell Immune Atlas of Triple Negative Breast Cancer Reveals Novel Immune Cell Subsets

Author

Qiu, Si, primary, Hong, Ruoxi, additional, Zhuang, Zhenkun, additional, Li, Yuan, additional, Zhu, Linnan, additional, Lin, Xinxin, additional, Zheng, Qiufan, additional, Liu, Shang, additional, Zhang, Kai, additional, Huang, Mengxian, additional, Lee, Kaping, additional, Lu, Qianyi, additional, Xia, Wen, additional, Xu, Fei, additional, Wang, Xi, additional, Tang, Jun, additional, Xiao, Xiangsheng, additional, Wei, Weidong, additional, Yuan, Zhongyu, additional, Shi, Yanxia, additional, Hou, Yong, additional, Zhang, Xiuqing, additional, Wang, Jian, additional, Yang, Huanming, additional, Zhan, Qimin, additional, Li, Bo, additional, and Wang, Shusen, additional

Published
2019
Full Text
View/download PDF

40. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer

Author

Zhang, Yaxiong, primary, Chang, Lianpeng, additional, Yang, Yunpeng, additional, Fang, Wenfeng, additional, Guan, Yanfang, additional, Wu, Aiwei, additional, Hong, Shaodong, additional, Zhou, Huaqiang, additional, Chen, Gang, additional, Chen, Xi, additional, Zhao, Shen, additional, Zheng, Qiufan, additional, Pan, Hui, additional, Zhang, Lanjun, additional, Long, Hao, additional, Yang, Haoxian, additional, Wang, Xin, additional, Wen, Zhesheng, additional, Wang, Junye, additional, Yang, Hong, additional, Xia, Xuefeng, additional, Zhao, Yuanyuan, additional, Hou, Xue, additional, Ma, Yuxiang, additional, Zhou, Ting, additional, Zhang, Zhonghan, additional, Zhan, Jianhua, additional, Huang, Yan, additional, Zhao, Hongyun, additional, Zhou, Ningning, additional, Yi, Xin, additional, and Zhang, Li, additional

Published
2019
Full Text
View/download PDF

43. Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer

Author

Zheng, Qiufan, Xu, Fei, Nie, Man, Xia, Wen, Qin, Tao, Qin, Ge, An, Xin, Xue, Cong, Peng, Roujun, Yuan, Zhongyu, Shi, Yanxia, and Wang, Shusen

Subjects
Adult, Aged, 80 and over, Selective Estrogen Receptor Modulators, nutritional and metabolic diseases, Observational Study, Breast Neoplasms, Middle Aged, Prognosis, digestive system, Survival Analysis, digestive system diseases, Tamoxifen, Non-alcoholic Fatty Liver Disease, Humans, Regression Analysis, Female, Toremifene, Research Article, Aged, Retrospective Studies, Ultrasonography
Abstract

Selective estrogen receptor modulator (SERM)-associated nonalcoholic fatty liver disease (NAFLD) might be related to treatment efficacy in patients with breast cancer because of circulating estrogen antagonism. The aim of the study was to investigate the relationship between NAFLD and survival outcomes in patients with breast cancer who were treated with tamoxifen or toremifene. This single-center, retrospective, cohort study included 785 eligible patients who received tamoxifen or toremifene, after curative resection for breast cancer, at the Sun Yat-sen University Cancer Center between January 2005 and December 2009. Data were extracted from patient medical records. All patients underwent abdominal ultrasonography, at least once, at baseline and at the annual follow-up. Patients who were diagnosed with NAFLD on ultrasonography were classified into the NAFLD or the non-NAFLD arm at the 3-year follow-up visit. Univariate and multivariate Cox regression analyses were conducted to evaluate any associations between NAFLD and disease-free survival (DFS) or overall survival (OS). One hundred fifty-eight patients were diagnosed with NAFLD. Patients who developed NAFLD had better DFS and OS compared with those who did not. Univariate analyses revealed that the 5-year DFS rates were 91.56% and 85.01% for the NAFLD and non-NAFLD arms, respectively (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.37–0.96; log-rank P = 0.032). The 5-year OS rates were 96.64% and 93.31% for the NAFLD and non-NAFLD arms, respectively (HR, 0.39; 95% CI, 0.16–0.99; log-rank P = 0.039). Multivariate analysis revealed that NAFLD was an independent prognostic factor for DFS, improving the DFS rate by 41% compared with that in the non-NAFLD arm (HR, 0.59; 95% CI, 0.36–0.96; P = 0.033). SERM-associated NAFLD was independently associated with improved DFS and might be useful for predicting treatment responses in breast cancer patients treated with SERMs.

Published
2015

44. Fulvestrant as maintenance therapy after first-line chemotherapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer (FANCY), a prospective, multicenter, single arm phase 2 study.

Author

Wang, Shusen, primary, Zheng, Qiufan, additional, Xu, Fei, additional, Xia, Wen, additional, Ouyang, Quchang, additional, Pang, Danmei, additional, Yuan, Huimin, additional, Shi, Yanxia, additional, Peng, Roujun, additional, and Yuan, Zhongyu, additional

Published
2017
Full Text
View/download PDF

45. Clinical value of circulating <em>ESR1</em> mutations for patients with metastatic breast cancer: a meta-analysis.

Author

Zhang, Kai, Hong, Ruoxi, Xu, Fei, Xia, Wen, Kaping, Lee, Qin, Ge, Zheng, Qiufan, Lu, Qianyi, Shi, Yan Xia, Yuan, Zhong yu, and Wang, Shusen

Subjects
ESTROGEN receptors, METASTATIC breast cancer, GENETICS of breast cancer, BREAST cancer treatment, META-analysis
Abstract

Background: The clinical implication of plasma ESR1 mutations in the estrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who had progressed after prior aromatase inhibitor (AI)-based therapy remains controversial. We conducted the first meta-analysis to investigate the prognostic significance and predictive role of plasma ESR1 mutations in MBC patients with prior exposure to AI therapy. Materials and methods: We searched PubMed, Embase, and Cochrane Library databases for eligible studies. Meta-analysis was conducted to calculate combined hazard ratios (HRs) with 95% CIs for progression-free survival (PFS) and overall survival (OS). Subgroup and sensitivity analyses were also performed. Results: This study enrolled a total of 1,530 patients with ER-positive MBC cases from six articles, including 429 ESR1 mutation carriers (28.04%). Meta-analysis demonstrated that plasma ESR1 mutation carriers had significantly worse PFS (HR: 1.40, 95% CI: 1.17–1.66; P [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

47. Fulvestrant as maintenance therapy after first-line chemotherapy in postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer patients (FANCY): A prospective, multicenter, single arm phase II study.

Author

Wang, Shusen, primary, Xu, Fei, additional, Ouyang, Quchang, additional, Yuan, Zhongyu, additional, Pang, Danmei, additional, Yuan, Huimin, additional, Peng, Roujun, additional, Xia, Wen, additional, and Zheng, Qiufan, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results